Research
Inflammatory bowel disease: Potential new treatment target identified
Catharine Paddock
The University of Oxford conducted a study on more than 200 patients’ with inflammatory bowel disease as well as two cohorts from phase 3 clinical trials of infliximab and golimumab. Conclusions drawn from this study suggest that a small protein involved in the inflammatory process could represent an effective target for drugs. As current methods of treatment have little to no effect on 40% of IBD patients, these proposed drugs could introduce a new way of treating the disorder. This could potentially have a substantial effect on the lifestyles of millions of patients worldwide.
Crohn’s and Colitis Australia would like to thank Medical News Today for permission to use this article.
No comments found.
About the author
